Amgen Inc.

Introduction
Amgen Inc. is one of the world’s largest biotechnology companies, founded in 1980 in California. Known as a pioneer in biologics and human therapeutics, Amgen focuses on discovering, developing, manufacturing, and delivering innovative medicines. The company specializes in areas such as oncology, nephrology, cardiology, bone health, and inflammation. Its breakthroughs in biotechnology, including the development of recombinant DNA medicines, have positioned Amgen as a leader in advancing science-based therapies.

Mission and Vision

Mission: To serve patients by transforming the promise of science and biotechnology into therapies that restore health or save lives.
Vision: To be the world’s best human therapeutics company by leveraging innovation, science, and technology.

Products and Services

Oncology & Hematology: Kyprolis, Blincyto, and Lumakras.
Cardiovascular: Repatha (cholesterol treatment).
Nephrology: Sensipar, Parsabiv, and Epogen for kidney disease management.
Bone Health: Prolia and Evenity for osteoporosis.
Inflammation: Enbrel (autoimmune diseases).
Biosimilars: A growing portfolio of biosimilar medicines for oncology and immunology.

Growth and Innovation
Amgen has expanded its global reach and innovation pipeline through acquisitions, including Onyx Pharmaceuticals (2013) and Horizon Therapeutics (2023), which broadened its rare disease and autoimmune portfolios. The company is a leader in biomanufacturing, biologics, and biosimilars, and invests heavily in genetics and molecular biology to create first-in-class therapies.

Global Impact
Operating in more than 100 countries, Amgen medicines reach millions of patients worldwide. Its therapies for chronic diseases like cancer, heart disease, and osteoporosis have significantly improved patient outcomes. Amgen is also a leader in sustainability, committing to achieve carbon neutrality by 2027, and invests in health equity initiatives to expand access to biotechnology medicines globally.